Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Neurology Product Name: Dysport

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2021

            Details:

            Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks (and at least 16 weeks for pediatric upper limb spasticity).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Erenumab

            Therapeutic Area: Neurology Product Name: Aimovig

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bupivacaine

            Therapeutic Area: Neurology Product Name: Exparel

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery.